379 related articles for article (PubMed ID: 27018207)
21. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Colombat P; Lemevel A; Bertrand P; Delwail V; Rachieru P; Brion A; Berthou C; Bay JO; Delepine R; Desablens B; Camilleri-Broët S; Linassier C; Lamy T
Bone Marrow Transplant; 2006 Sep; 38(6):417-20. PubMed ID: 16951691
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
25. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.
Alimohamed N; Daly A; Owen C; Duggan P; Stewart DA
Leuk Lymphoma; 2012 May; 53(5):862-7. PubMed ID: 22023529
[TBL] [Abstract][Full Text] [Related]
26. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
27. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
28. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
Kuitunen H; Tokola S; Siniluoto T; Isokangas M; Sonkajärvi E; Alahuhta S; Turpeenniemi-Hujanen T; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
J Neurooncol; 2017 Jan; 131(2):293-300. PubMed ID: 27752883
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
[TBL] [Abstract][Full Text] [Related]
30. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
[TBL] [Abstract][Full Text] [Related]
31. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Young PA; Gaut D; Kimaiyo DK; Grotts J; Romero T; Chute J; Schiller G; de Vos S; Eradat HA; Timmerman J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):468-479. PubMed ID: 32229199
[TBL] [Abstract][Full Text] [Related]
32. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM
Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937
[TBL] [Abstract][Full Text] [Related]
34. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
Illerhaus G; Kasenda B; Ihorst G; Egerer G; Lamprecht M; Keller U; Wolf HH; Hirt C; Stilgenbauer S; Binder M; Hau P; Edinger M; Frickhofen N; Bentz M; Möhle R; Röth A; Pfreundschuh M; von Baumgarten L; Deckert M; Hader C; Fricker H; Valk E; Schorb E; Fritsch K; Finke J
Lancet Haematol; 2016 Aug; 3(8):e388-97. PubMed ID: 27476790
[TBL] [Abstract][Full Text] [Related]
35. HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA.
Cheng Kiat Ng L; Shwei Wen Tham C; Wei Inng Lim F; Chen Y; Yeu Ong S; Nagarajan C; Lee JJ; Tee Goh Y; Linn YC; Shan Lee Y; Diong Phipps C; Kim Siang Quek J; Hein T; Cheng Hwang JC; Grigoropoulos N; Khee Hwang WY; Yew Leng Ho A
Blood Cell Ther; 2021 Nov; 4(4):92-100. PubMed ID: 36714065
[TBL] [Abstract][Full Text] [Related]
36. First-line autologous stem cell transplantation in primary CNS lymphoma.
Brevet M; Garidi R; Gruson B; Royer B; Vaida I; Damaj G
Eur J Haematol; 2005 Oct; 75(4):288-92. PubMed ID: 16146534
[TBL] [Abstract][Full Text] [Related]
37. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
[TBL] [Abstract][Full Text] [Related]
38. Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.
Miyao K; Sakemura R; Imai K; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
Int J Hematol; 2014 Aug; 100(2):152-8. PubMed ID: 24947495
[TBL] [Abstract][Full Text] [Related]
39. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Omuro A; Correa DD; DeAngelis LM; Moskowitz CH; Matasar MJ; Kaley TJ; Gavrilovic IT; Nolan C; Pentsova E; Grommes CC; Panageas KS; Baser RE; Faivre G; Abrey LE; Sauter CS
Blood; 2015 Feb; 125(9):1403-10. PubMed ID: 25568347
[TBL] [Abstract][Full Text] [Related]
40. Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas.
Wu M; Wang X; Xie Y; Liu W; Zhang C; Ping L; Ying Z; Deng L; Zheng W; Lin N; Tu M; Song Y; Zhu J
Int J Med Sci; 2018; 15(9):867-874. PubMed ID: 30008598
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]